{
    "eid": "2-s2.0-85024889277",
    "title": "Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates",
    "cover-date": "2017-07-04",
    "subject-areas": [
        {
            "$": "Immunology",
            "@code": "2403"
        },
        {
            "$": "Immunology and Allergy",
            "@code": "2723"
        }
    ],
    "keywords": [
        "Allometric scaling",
        "clearance",
        "clinical",
        "cynomolgus monkeys",
        "monoclonal antibodies",
        "non-specific clearance",
        "pharmacokinetics",
        "preclinical",
        "therapeutic proteins"
    ],
    "authors": [
        "Miroslav Dostalek"
    ],
    "citedby-count": 32,
    "ref-count": 76,
    "ref-list": [
        "The therapeutic monoclonal antibody market",
        "The Fab and Fc fragments of IgA1 exhibit a different arrangement from that in IgG: A study by X-ray and neutron solution scattering and homology modelling",
        "Therapeutic antibodies: Discovery, design and deployment",
        "Next-generation optimized biotherapeutics - A review and preclinical study",
        "Alpha Thalassaemia and extended alpha globin genes in Sri Lanka",
        "World J Biol Chem",
        "Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4",
        "Development of Motavizumab, an Ultra-potent Antibody for the Prevention of Respiratory Syncytial Virus Infection in the Upper and Lower Respiratory Tract",
        "Complex pharmacokinetics of a humanized antibody against human amyloid beta peptide, Anti-Abeta Ab2, in nonclinical species",
        "Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity",
        "A strategy for risk mitigation of antibodies with fast clearance",
        "In vitro potency, pharmacokinetic profiles, and pharmacological activity of optimized anti-IL-21R antibodies in a mouse model of lupus",
        "Reduced elimination of IgG antibodies by engineering the variable region",
        "In silico selection of therapeutic antibodies for development: Viscosity, clearance, and chemical stability",
        "Evaluating the use of antibody variable region (Fv) charge as a risk assessment tool for predicting typical cynomolgus monkey pharmacokinetics",
        "Efficient production of antibodies against a mammalian integral membrane protein by phage display",
        "Production, characterization and pharmacokinetic properties of antibodies with N-linked Mannose-5 glycans",
        "Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies",
        "Biologics: An update and challenge of their pharmacokinetics",
        "Neonatal Fc receptor: From immunity to therapeutics",
        "Developability assessment during the selection of novel therapeutic antibodies",
        "Developability studies before initiation of process development: Improving manufacturability of monoclonal antibodies",
        "Antibody engineering for increased potency, breadth and half-life",
        "Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies",
        "Target-independent variable region mediated effects on antibody clearance can be FcRn independent",
        "High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in mice",
        "Conferring the binding properties of the mouse MHC class I-related receptor, FcRn, onto the human ortholog by sequential rounds of site-directed mutagenesis",
        "Antibody structure, prediction and redesign",
        "Computational docking of antibody-antigen complexes, opportunities and pitfalls illustrated by influenza hemagglutinin",
        "Construction, MD simulation, and hydrodynamic validation of an all-atom model of a monoclonal IgG antibody",
        "Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics",
        "Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis",
        "Anti-p40 Antibodies Ustekinumab and Briakinumab: Blockade of Interleukin-12 and Interleukin-23 in the Treatment of Psoriasis",
        "Briakinumab",
        "Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents",
        "Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?",
        "Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pl reduces non-specific binding and improves the pharmacokinetics",
        "FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys",
        "Functions of cell surface heparan sulfate proteoglycans",
        "The sweet and sour of cancer: Glycans as novel therapeutic targets",
        "Binding of matrix metalloproteinase inhibitors to extracellular matrix: 3D-QSAR analysis",
        "Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: A FACS-based, high-throughput selection and analytical tool",
        "Determination and validation of off-target activities of anti-CD44 variant 6 antibodies using protein biochips and tissue microarrays",
        "An automated immunoassay for early specificity profiling of antibodies",
        "Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences",
        "A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life",
        "Increasing the serum persistence of an IgG fragment by random mutagenesis",
        "Comparative studies of rat IgG to further delineate the Fc:FcRn interaction site",
        "Monoclonal antibody clearance: Impact of modulating the interaction of IgG with the neonatal Fc receptor",
        "Properties of Human IgG1s engineered for enhanced binding to the neonatal Fc Receptor (FcRn)",
        "An engineered human IgG1 antibody with longer serum half-life",
        "Engineered Human IgG Antibodies with Longer Serum Half-lives in Primates",
        "Engineering human IgG1 affinity to human neonatal Fc receptor: Impact of affinity improvement on pharmacokinetics in primates",
        "A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life",
        "The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity",
        "Conformational destabilization of immunoglobulin G increases the low pH binding affinity with the neonatal Fc receptor",
        null,
        "A good practice guide to the administration of substances and removal of blood, including routes and volumes",
        "Discovery pharmacokinetic studies in mice using serial microsampling, dried blood spots and microbore LC-MS/MS",
        "Pharmacokinetic applications of microdevices and microsampling techniques",
        "Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: Potential application in humorally mediated autoimmune disease",
        "Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities",
        "Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody",
        "Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies",
        "Human FcRn transgenic mice for pharmacokinetic evaluation of therapeutic antibodies",
        "Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies",
        "Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: What have we learned?",
        "Quantitative prediction of human pharmacokinetics for monoclonal antibodies: Retrospective analysis of monkey as a single species for first-in-human prediction",
        "Prediction of human clearance of therapeutic proteins: Simple allometric scaling method revisited",
        "Prediction of human pharmacokinetics of therapeutic monoclonal antibodies from simple allometry of monkey data",
        "Reviews: Interspecies scaling of therapeutic monoclonal antibodies: Initial look",
        "Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations",
        "ADME of biologics-what have we learned from small molecules?",
        "Population pharmacokinetics of therapeutic monoclonal antibodies",
        "ADME of biologics-what have we learned from small molecules?",
        "Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: Comparative evaluation of prediction approaches in early drug development"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "San Francisco",
            "affilname": "Genentech, Inc",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Lexington",
            "affilname": "Drug Metabolism and Pharmacokinetics",
            "affiliation-country": "United States"
        }
    ],
    "funding": []
}